The Radiation Resources Core Facility (RRCF) provides an essential service to the Cancer Center, since ionizing radiation has both carcinogenic and therapeutic roles in cancer and can produce viable, but nonreproductive cells tor a variety of other studies. The Facility serves two types of cancer researchers: those studying the cancer-causing and cancer-treating actions of radiation, and those with primary interests in other topics for whom radiation is an essential tool, e.g. for killing cells to prepare feeder layers for growth of embryonic stem cells, or to study the immunogenic properties of cancer cells. The RRCF is directed by Nancy L. Oleinick, PhD, and managed by John Mulvihill, MS, both of whom have held these positions since the founding of the Cancer Center. The objectives of the RRCF are: (1) To maintain and operate ionizing radiation-producing devices for cancer researchers; (2) To consult with users concerning the instrumentation, the services, the training requirements, and if desired, the experimental design (3) To train new users in proper operation of the equipment; and (4) To document usage by keeping and reviewing user logs. The RRCF provides three gamma-irradiators, two located in a 256-sq. ft. room in Cancer Center space in the Biomedical Research Building (BRB), and one located in a 58-sq. ft. area within the barrier facility of the Cancer Center's Athymic Animal Facility in the Wolstein Research Laboratories. A low-dose-rate lr-192 irradiator is housed in a shielded inner room within the BRB area. Ancillary equipment for cell handling is also provided in Cancer Center space adjacent to the BRB irradiator room. Mr. Mulvihill trains users in the proper and safe use of the irradiators and occasionally carries out irradiations for users when requested. Dr. Oleinick consults with users on protocols and dosages to accomplish their research goals. Because of cost, licensing, and requirement for expertise, it would be impractical for the many cancer researchers to maintain their own irradiators; thus, this facility provides essential equipment and service to cancer researchers in an efficient and cost-effective manner.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-19
Application #
7599140
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
19
Fiscal Year
2008
Total Cost
$74,084
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143
Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279

Showing the most recent 10 out of 1227 publications